GEOGRAPHIC ATROPHY (GA)
Clinical trials for GEOGRAPHIC ATROPHY (GA) explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY (GA) trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY (GA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to halt blinding eye disease
Disease control Recruiting nowThis phase 3 trial tests two injectable drugs, pozelimab and cemdisiran, alone or together, to slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes central vision loss. About 975 participants will receive either the drugs or a…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New eye drug trial aims to slow vision loss from geographic atrophy
Disease control Recruiting nowThis early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA) — a condition where parts of the retina stop working, leading to vision loss. The main goal is to check the drug's safety and tolerabili…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New eye injection aims to halt blindness from dry AMD in major trial
Disease control Recruiting nowThis study tests an experimental drug called ONL1204, given as an eye injection, to see if it can slow the growth of blind spots in people with geographic atrophy, an advanced form of dry age-related macular degeneration. About 324 adults aged 55 and older will receive either the…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE2 • Sponsor: ONL Therapeutics • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC